Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 383

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults

Open access
Menzies, Dick, Adjobimey, Menonli, Ruslami, Rovina, Trajman, Anete, Sow, Oumou, Kim, Heejin, Obeng Baah, Joseph, Marks, Guy B., Long, Richard, Hoeppner, Vernon, Elwood, Kevin, Al-Jahdali, Hamdan, Gninafon, Martin, Apriani, Lika, Koesoemadinata, Raspati C., Kritski, Afranio, Rolla, Valeria, Bah, Boubacar, Camara, Alioune, Boakye, Isaac, Cook, Victoria J., Goldberg, Hazel, Valiquette, Chantal, Hornby, Karen, Dion, Marie-Josée, Li, Pei-Zhi, Hill, Philip C., Schwartzman, Kevin, Benedetti, Andrea·2018·New England Journal of Medicine

Abstract

BACKGROUND: A 9-month regimen of isoniazid can prevent active tuberculosis in persons with latent tuberculosis infection. However, the regimen has been associated with poor adherence rates and with toxic effects. METHODS: In an open-label trial conducted in nine countries, we randomly assigned adults with latent tuberculosis infection to receive treatment with a 4-month regimen of rifampin or a 9-month regimen of isoniazid for the prevention of confirmed active tuberculosis within 28 months after randomization. Noninferiority and potential superiority were assessed. Secondary outcomes included clinically diagnosed active tuberculosis, adverse events of grades 3 to 5, and completion of the treatment regimen. Outcomes were adjudicated by independent review panels. RESULTS: Among the 3443 patients in the rifampin group, confirmed active tuberculosis developed in 4 and clinically diagnosed active tuberculosis developed in 4 during 7732 person-years of follow-up, as compared with 4 and 5 patients, respectively, among 3416 patients in the isoniazid group during 7652 person-years of follow-up. The rate differences (rifampin minus isoniazid) were less than 0.01 cases per 100 person-years (95% confidence interval [CI], -0.14 to 0.16) for confirmed active tuberculosis and less than 0.01 cases per 100 person-years (95% CI, -0.23 to 0.22) for confirmed or clinically diagnosed tuberculosis. The upper boundaries of the 95% confidence interval for the rate differences of the confirmed cases and for the confirmed or clinically diagnosed cases of tuberculosis were less than the prespecified noninferiority margin of 0.75 percentage points in cumulative incidence; the rifampin regimen was not superior to the isoniazid regimen. The difference in the treatment-completion rates was 15.1 percentage points (95% CI, 12.7 to 17.4). The rate differences for adverse events of grade 3 to 5 occurring within 146 days (120% of the 4-month planned duration of the rifampin regimen) were -1.1 percentage points (95% CI, -1.9 to -0.4) for all events and -1.2 percentage points (95% CI, -1.7 to -0.7) for hepatotoxic events. CONCLUSIONS: The 4-month regimen of rifampin was not inferior to the 9-month regimen of isoniazid for the prevention of active tuberculosis and was associated with a higher rate of treatment completion and better safety. (Funded by the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council; ClinicalTrials.gov number, NCT00931736 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1714283

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 383

Metadata

Authors
Menzies, D., Adjobimey, M., Ruslami, R., Trajman, A., Sow, O., Kim, H., Obeng Baah, J., Marks, G. B., Long, R., Hoeppner, V., Elwood, K., Al-Jahdali, H., Gninafon, M., Apriani, L., Koesoemadinata, R. C., Kritski, A., Rolla, V., Bah, B., Camara, A., Boakye, I., Cook, V. J., Goldberg, H., Valiquette, C., Hornby, K., Dion, M.-J., Li, P.-Z., Hill, P. C., Schwartzman, K., & Benedetti, A.
Venue
New England Journal of Medicine
Published
2018-08-02
Volume
379
Issue
5
Pages
440-453
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2886632226
Cited by
383
References
31
FWCI
33.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. https://app.cochat.ai/papers/10.1056/nejmoa1714283
The paper
Menzies, D., Adjobimey, M., Ruslami, R., Trajman, A., Sow, O., Kim, H., Obeng Baah, J., Marks, G. B., Long, R., Hoeppner, V., Elwood, K., Al-Jahdali, H., Gninafon, M., Apriani, L., Koesoemadinata, R. C., Kritski, A., Rolla, V., Bah, B., Camara, A., . . . Benedetti, A. (2018). Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1714283

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.